Immuno-Oncology Virtual Grand Rounds

A Series on Lung Cancer, Melanoma, and Bladder Cancer

Not a member of My prIME? Join now for instant access.

Stay engaged in the latest updates on immuno-oncology in lung cancer, melanoma, and bladder cancer with this virtual grand rounds series. Each month you can participate in a new live webinar featuring an expert speaking on recent updates and key findings in immuno-oncology. You can access these webinars through your desktop computer, iPhone, iPad, and Android devices. Don’t miss out on this exciting series.



1.0 AMA PRA Category 1 Credit™

Weighing the Options in Melanoma Immunotherapy

Tuesday, 27 November 2018
07.00 – 08.00 Central European Time

Register Now

Christian U. Blank, MD, PhD
Netherlands Cancer Institute
Amsterdam, the Netherlands

Looking Forward: Where Are We Headed With Immunotherapy in Bladder Cancer

Tuesday, 18 December 2018
08.00 – 09.00 Central European Time

Register Now

Yohann Loriot, MD, PhD
Gustave Roussy
Villejuif, France


  • Benjamin Besse, MD, PhDGustave Roussy
    Villejuif, France
  • Ronald de Wit, MD, PhDErasmus MC
    Rotterdam, the Netherlands
  • Dirk Schadendorf, MDUniversity Hospital Essen
    Essen, Germany

This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer, melanoma, or bladder cancer.

After successful completion of this educational activity, participants should be able to:

  • Examine the evidence for the role of biomarkers in immuno-oncology and how to apply them in clinical practice
  • Select optimal immunotherapy approach for patients with cancer
  • Describe the rationale for combination therapies of immunotherapeutic agents with each other, with chemotherapy, and with targeted agents
  • Develop strategies to recognize and manage adverse events resulting from the use of immunotherapies

This educational activity is supported by a grant from Merck Sharp and Dohme Corp.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.